Viking Therapeutics, Inc.
VKTX
$33.20
-$1.22-3.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.44% | -7.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 34.44% | 19.96% | |||
| Operating Income | -34.44% | -19.96% | |||
| Income Before Tax | -43.68% | -28.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -43.68% | -28.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -43.68% | -28.83% | |||
| EBIT | -34.44% | -19.96% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -43.59% | -28.01% | |||
| Normalized Basic EPS | -43.58% | -28.02% | |||
| EPS Diluted | -43.59% | -28.01% | |||
| Normalized Diluted EPS | -43.58% | -28.02% | |||
| Average Basic Shares Outstanding | 0.06% | 0.65% | |||
| Average Diluted Shares Outstanding | 0.06% | 0.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||